Two-week and 6-week human engraftment from Lin^–CD34⁺CD38^+/lo SRCs in the RF and BM of various NOD/SCID mouse models. Lin^–CD34⁺CD38^+/lo cells were transplanted into 6 different xenotransplantation models: NOD/SCID-β2m^–/– mice (β2m^–/–), anti-CD122 (α-CD122)–treated or untreated NOD/SCID mice, each intravenous (IV) or intrafemoral (IF) injection. Percentage of human cell engraftment in the RF (A) or BM (noninjected left femur, 2 tibiae, and pelvis BM; B) of 2-week engrafted mice was determined by flow cytometry. Bars represent myelolymphoid (CD45⁺; □), erythroid (CD45^–CD36⁺ glycophorin A⁺; ▦), and the combined total (▪) of the human graft (n = 76 mice from 5 experiments). (C) Percentage of human CD45⁺ cell engraftment in the RF (▨) and BM (▦) of the 6 xenotransplantation models evaluated at 6 weeks after transplantation (n = 34 mice from 3 experiments). *P < .05 versus α-CD122 IF; ♦, P < .05 versus α-CD122 IV; , P < .05 versus β2m^–/–IF; ‡P < .05 versus β2m^–/–IV. Error bars represent SEM.